Moonshots with Peter Diamandis David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #250
295 snips
Apr 27, 2026 
David Sinclair, Harvard genetics professor and longevity biotech entrepreneur, dives into human age-reversal trials, why the eye is the first proving ground, and the race from gene therapy to a scalable longevity pill. He also gets into lifespan timelines, his current routine, heart-risk tracking, diet changes, and the role of sleep, stress, and social connection.
AI Snips
Chapters
Books
Transcript
Episode notes
Human OSK Reprogramming Reaches The Clinic
- David Sinclair says the first human epigenetic reprogramming trial will deliver three Yamanaka factors OSK into the eye to try restoring vision.
- In mice, similar reprogramming reversed aging markers in brain, muscle, kidney, liver, skin, joints, and immune tissue.
AI Driven Longevity Pill Could Cut Costs Drastically
- Sinclair Lab moved beyond pricey AAV delivery and now uses AI to search for small molecules that mimic OSK-driven rejuvenation.
- David Sinclair says a pill could eventually cost like metformin, after screening billions of molecules and testing reversal in old human cells.
Why Age Reversal Feels Like The Wright Brothers
- Sinclair frames age reversal as a Wright Brothers moment where proving it once would transform what medicine thinks is possible.
- He says many labs and investors now back the field, so progress should continue even if one program hits setbacks.
